Derazantinib clinical trials
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses derazantinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
Basilea Pharmaceutica (4) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses derazantinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/RearrangementsActive, not recruitingPhase 2Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT05174650Written as Derazantinib
- Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric AdenocarcinomaTerminatedPhase 1/2Basilea PharmaceuticaNCT04604132Written as Derazantinib
- Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic CholangiocarcinomaCompletedPhase 2Basilea PharmaceuticaNCT03230318Written as derazantinib
- Derazantinib and Atezolizumab in Patients With Urothelial CancerCompletedPhase 1/2Basilea PharmaceuticaNCT04045613Written as Derazantinib 300 mg once daily monotherapy
- Mass Balance and Pharmacokinetics Study of Derazantinib in Healthy Male SubjectsCompletedPhase 1Basilea PharmaceuticaNCT04098692Written as Derazantinib capsule
Codes
What other systems call derazantinib · ClinicalTrials.gg INT000757
- MeSH (NLM) C000621805derazantinibOne source NLM
- UNII (FDA) N9B0H171MJDERAZANTINIBConfirmed FDA, NLM
- NCI Thesaurus C104267DerazantinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000621805 | derazantinib | One source NLM |
| UNII (FDA) | N9B0H171MJ | DERAZANTINIB | Confirmed FDA, NLM |
| NCI Thesaurus | C104267 | Derazantinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.